[go: up one dir, main page]

ATE309378T1 - Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung - Google Patents

Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung

Info

Publication number
ATE309378T1
ATE309378T1 AT97953786T AT97953786T ATE309378T1 AT E309378 T1 ATE309378 T1 AT E309378T1 AT 97953786 T AT97953786 T AT 97953786T AT 97953786 T AT97953786 T AT 97953786T AT E309378 T1 ATE309378 T1 AT E309378T1
Authority
AT
Austria
Prior art keywords
weakened
vehicle
strain used
oral immunization
salmonella strain
Prior art date
Application number
AT97953786T
Other languages
English (en)
Inventor
Ayub Darji
N Carlos Guzm
Kenneth Timmis
Juergen Wehland
Siegfried Weiss
Birgit Gerstel
Trinad Chakraborty
Petra Wachholz
Original Assignee
Biotechnolog Forschung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8226707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE309378(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotechnolog Forschung Gmbh filed Critical Biotechnolog Forschung Gmbh
Application granted granted Critical
Publication of ATE309378T1 publication Critical patent/ATE309378T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97953786T 1997-04-18 1997-12-11 Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung ATE309378T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97106503 1997-04-18
PCT/EP1997/006933 WO1998048026A1 (en) 1997-04-18 1997-12-11 Attenuated salmonella strain used as a vehicle for oral immunization

Publications (1)

Publication Number Publication Date
ATE309378T1 true ATE309378T1 (de) 2005-11-15

Family

ID=8226707

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97953786T ATE309378T1 (de) 1997-04-18 1997-12-11 Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung

Country Status (10)

Country Link
US (1) US7115269B2 (de)
EP (1) EP0977874B1 (de)
JP (1) JP2002513287A (de)
AT (1) ATE309378T1 (de)
AU (1) AU5756298A (de)
CA (1) CA2286210A1 (de)
DE (1) DE69734605T2 (de)
DK (1) DK0977874T3 (de)
ES (1) ES2253789T3 (de)
WO (1) WO1998048026A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US6682729B1 (en) 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
AU3210997A (en) * 1996-05-24 1997-12-09 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
DE19754938B4 (de) * 1997-12-11 2006-04-20 Christoph von Dr. Eichel-Streiber TGC-Verfahren zur Induktion einer zielgerichteten, somatischen Transgenität
MXPA01005615A (es) 1998-12-04 2004-08-19 Univ Manitoba Procedimiento de inmunizacion en dos pasos para proteger contra infeccion por chlamydia.
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
DE60131430T2 (de) 2000-01-14 2008-10-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
IL151942A0 (en) 2000-03-29 2003-04-10 Univ Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
AU2001292035A1 (en) * 2000-09-29 2002-04-08 Microscience Limited Attenuated salmonella microorganisms comprising a mutation in the sifa gene
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
WO2003054161A2 (en) 2001-12-20 2003-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
DE10326189A1 (de) * 2003-06-06 2005-01-05 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Bakterielle Träger für Nukleotidsequenzen kodierend für Wirkstoffe
WO2005026203A2 (en) 2003-09-18 2005-03-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna promoters and anthrax vaccines
US20070224205A1 (en) 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
DK2977456T3 (en) 2006-08-15 2018-01-22 Univ Pennsylvania Compositions comprising HMW-MAA and fragments thereof for the treatment of cancer
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
JP5539411B2 (ja) 2009-03-04 2014-07-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 血管新生因子を含む組成物およびその使用方法
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
JP5981436B2 (ja) 2010-10-01 2016-08-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用
EP3332804A1 (de) 2011-03-11 2018-06-13 Advaxis, Inc. Adjuvanzien auf listerien-basis
EP2825195A4 (de) 2012-03-12 2015-10-07 Advaxis Inc Hemmung einer suppressorzellfunktion nach einer behandlung mit einem listerienimpfstoff
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
EP2988762B1 (de) 2013-04-25 2018-06-06 Vaximm AG Salmonella-vektoren für die krebsimmuntherapie gerichtet gegen das wilms-tumor-gen wt1
CA3069523A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
KR102869944B1 (ko) 2018-07-11 2025-10-15 액팀 테라퓨틱스, 인코퍼레이티드 조작된 면역자극성 박테리아 균주 및 이의 용도
EP3844276A2 (de) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Manipulierte immunstimulierende bakterienstämme und verwendungen davon
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231176A (en) * 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
WO1989001514A1 (en) * 1987-08-10 1989-02-23 The University Of Melbourne Molecular cloning of human rotavirus serotype 4 gene 9 encoding vp7, the major outer capsid neutralisation specific glycoprotein and expression of vp7 and fragments thereof for use in a vaccine
US5986061A (en) * 1988-10-28 1999-11-16 Pbl Biomedical Laboratories Phosphorylated fusion proteins
CA2096529C (en) * 1990-11-21 2003-01-21 Roy Curtiss, Iii Recombinant avirulent salmonella antifertility vaccines
US5736388A (en) * 1994-12-30 1998-04-07 Chada; Sunil Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US6682729B1 (en) 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US6150170A (en) 1998-05-03 2000-11-21 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US5869057A (en) * 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance
US5824538A (en) * 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
CA2231332C (en) * 1995-09-06 2007-04-17 Arthur A. Branstrom Bacterial delivery system
US5866340A (en) * 1996-03-22 1999-02-02 Johns Hopkins University Selective expression of desired genes in cells expressing oncoproteins
US6099848A (en) * 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US6365576B1 (en) * 1999-06-24 2002-04-02 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for inhibiting herpes infection

Also Published As

Publication number Publication date
CA2286210A1 (en) 1998-10-29
EP0977874A1 (de) 2000-02-09
JP2002513287A (ja) 2002-05-08
US20030180320A1 (en) 2003-09-25
AU5756298A (en) 1998-11-13
ES2253789T3 (es) 2006-06-01
EP0977874B1 (de) 2005-11-09
DE69734605D1 (de) 2005-12-15
DK0977874T3 (da) 2006-03-20
US7115269B2 (en) 2006-10-03
WO1998048026A1 (en) 1998-10-29
DE69734605T2 (de) 2006-08-03

Similar Documents

Publication Publication Date Title
ATE309378T1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
IL161832A0 (en) Pharmaceutical composition for inducing an immune response in a human or animal
PL322015A1 (en) Derivatives of hydroxylamine useful as compounds enhancing production of accompanying molecular protein and ethod of obtaining them
MXPA03001622A (es) Peptidos que atraviesan membranas y sus usos.
ES2102196T3 (es) Periferializacion de celulas pluripotenciales hematopoyeticas.
MX9710479A (es) Extracto de iridaceas y composiciones que la contienen.
DE69635609D1 (de) Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung
IL148060A0 (en) Compositions and methods for improved cell culture
DK1115840T3 (da) Afstamningsspecifikke celler og progenitorceller
PL365246A1 (en) Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions
HUP9800731A2 (hu) Eljárás ivarsejt osztódás stimulálására
ES2181501T3 (es) Composicion cosmetica.
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
ES2249058T3 (es) Factores de preservacion de celulas progenitoras y metodos y productos relacionados.
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
DE60108661D1 (de) Herstellung und verwendung von dendritischen zellen
AR003407A1 (es) Procedimiento de clonacion de un acido nucleico que codifica una proteina con actividad de delta-5,7-esterol, delta-7-reductasa, procedimiento de preparacion de la proteina, procemiento de reduccion in vitro de un esterol insaturado, procedimiento de produccion de pregnenolona, cepa de levadura transformada y metodo de diagnostico in vitro para la deteccion de la deficiencia de delta-5, 7-esterol, delta-7-reductasa
GB9612214D0 (en) Vaccine
EP1246647A4 (de) Nicht-immunsuppresives hiv tat-protein
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use
WO1999064439A3 (en) Methods for increasing cationic antimicrobial peptides
PT1230261E (pt) Derivados nonapeptídicos de ny-eso-1 e suas utilizações
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
PT1178960E (pt) Analogos da vitamina d e sua utilizacao farmaceutica

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0977874

Country of ref document: EP